Nanoparticles Could Help in Screening Individuals for Thalassaemia

A type of nanoparticles could provide clues to whether a person carries the defective gene for thalassaemia, claims a research team from Kolkata-based Calcutta University. Known as copper nanoparticles (CuNPs), the nanomolecules form various protein aggregates binding to haemoglobin, the metalloprotein in red blood cells. Besides protein aggregrates, the copper nanoparticles also precipitate the aggregated protein.

The researchers found that the nanoparticles formed a distinct aggregation when bound to a mutated form of haemoglobin that leads to beta-thalassaemia. Using special techniques like atomic absorption spectroscopy and high-pressure liquid chromatography, the team found the nanoparticles were co-precipitated with specific variants of haemoglobin. Studies showed that protein initially broke the nanoclusters into smaller sizes (4nm), followed by gradual increase in cluster size. A suitable scaling up of the approach may have important implications in screening haemoglobinopathies such beta-thalassaemia, write the researchers in a recent issue of Nanomedicine.

According to an estimate, there would be about 45 million carriers and about 15,000 infants born each year with haemoglobinopathies in India. The carrier frequency of haemoglobinopathy varies from 3 to 17 per cent in different population groups of India. In India, beta-thalassaemia comprises about 80–90 per cent of the total thalassaemias reported. More than 200 beta-thalassaemia mutations have been identified all over the world and of these about 28 mutations have been documented in Indian patients. There is growing concern that thalassemia may become a very serious problem in the next 50 years.